Your browser doesn't support javascript.
loading
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial.
Petrylak, Daniel P; de Wit, Ronald; Chi, Kim N; Drakaki, Alexandra; Sternberg, Cora N; Nishiyama, Hiroyuki; Castellano, Daniel; Hussain, Syed A; Fléchon, Aude; Bamias, Aristotelis; Yu, Evan Y; van der Heijden, Michiel S; Matsubara, Nobuaki; Alekseev, Boris; Necchi, Andrea; Géczi, Lajos; Ou, Yen-Chuan; Coskun, Hasan Senol; Su, Wen-Pin; Bedke, Jens; Gakis, Georgios; Percent, Ivor J; Lee, Jae-Lyun; Tucci, Marcello; Semenov, Andrey; Laestadius, Fredrik; Peer, Avivit; Tortora, Giampaolo; Safina, Sufia; Garcia Del Muro, Xavier; Rodriguez-Vida, Alejo; Cicin, Irfan; Harputluoglu, Hakan; Tagawa, Scott T; Vaishampayan, Ulka; Aragon-Ching, Jeanny B; Hamid, Oday; Liepa, Astra M; Wijayawardana, Sameera; Russo, Francesca; Walgren, Richard A; Zimmermann, Annamaria H; Hozak, Rebecca R; Bell-McGuinn, Katherine M; Powles, Thomas.
Afiliación
  • Petrylak DP; Yale School of Medicine, Yale University, New Haven, CT, USA. Electronic address: daniel.petrylak@yale.edu.
  • de Wit R; Erasmus MC Cancer Institute, Rotterdam, Netherlands.
  • Chi KN; British Columbia Cancer Agency, Vancouver, BC, Canada.
  • Drakaki A; David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
  • Sternberg CN; San Camillo and Forlanini Hospitals, Rome, Italy.
  • Nishiyama H; University of Tsukuba, Tsukuba, Ibaraki, Japan.
  • Castellano D; Hospital Universitario 12 de Octubre (CiberOnc), Madrid, Spain.
  • Hussain SA; Department of Oncology and Metabolism, Medical School, University of Sheffield, Sheffield, UK.
  • Fléchon A; Centre Léon Bérard, Lyon, France.
  • Bamias A; National and Kapodistrian University of Athens, Athens, Greece.
  • Yu EY; University of Washington, Seattle, WA, USA.
  • van der Heijden MS; Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, Amsterdam, Netherlands.
  • Matsubara N; National Cancer Center Hospital East, Chiba, Japan.
  • Alekseev B; P.A. Herzen Moscow Oncological Research Institute, Moscow, Russia.
  • Necchi A; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Istituto Nazionale dei Tumori, Milan, Italy.
  • Géczi L; National Institute of Oncology, Budapest, Hungary.
  • Ou YC; Tungs' Taichung Metro Harbor Hospital, Taichung, Taiwan.
  • Coskun HS; Akdeniz University School of Medicine, Antalya, Turkey.
  • Su WP; Institute of Clinical Medicine, College of Medicine, National Cheng Kung University & Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
  • Bedke J; Department of Urology, University of Tübingen, Tübingen, Germany.
  • Gakis G; Department of Urology, University of Tübingen, Tübingen, Germany; Pediatric Urology, Julius Maximillians University, Würzburg, Germany.
  • Percent IJ; Florida Cancer Specialists, Port Charlotte, FL, USA.
  • Lee JL; Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.
  • Tucci M; Division of Medical Oncology, Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Turin, Italy.
  • Semenov A; RBHI Ivanovo Regional Oncology Dispensary, Ivanovo, Russia.
  • Laestadius F; Centre Oscar Lambret, Lille, France.
  • Peer A; Rambam Health Care Campus, Haifa, Israel.
  • Tortora G; University of Verona and Azienda Ospedaliera Universitaria Integrata, Verona, Italy.
  • Safina S; Tatarstan Regional Cancer Center, Kazan, Russia.
  • Garcia Del Muro X; Institut Català d'Oncologia L'Hospitalet, Institut d'Investigacio Biomedica de Bellvitge, University of Barcelona, Barcelona, Spain.
  • Rodriguez-Vida A; Hospital del Mar, Barcelona, Spain.
  • Cicin I; Trakya University, Edirne, Turkey.
  • Harputluoglu H; Inonu University, Malatya, Turkey.
  • Tagawa ST; New York-Presbyterian/Weill Cornell Medical Center, New York, NY, USA.
  • Vaishampayan U; Karmanos Cancer Institute, Detroit, MI, USA.
  • Aragon-Ching JB; Inova Schar Cancer Institute, Fairfax, VA, USA.
  • Hamid O; Eli Lilly and Company, Indianapolis, IN, USA.
  • Liepa AM; Eli Lilly and Company, Indianapolis, IN, USA.
  • Wijayawardana S; Eli Lilly and Company, Indianapolis, IN, USA.
  • Russo F; Eli Lilly and Company, Indianapolis, IN, USA.
  • Walgren RA; Eli Lilly and Company, Indianapolis, IN, USA.
  • Zimmermann AH; Eli Lilly and Company, Indianapolis, IN, USA.
  • Hozak RR; Eli Lilly and Company, Indianapolis, IN, USA.
  • Bell-McGuinn KM; Eli Lilly and Company, Indianapolis, IN, USA.
  • Powles T; Barts Cancer Institute, Queen Mary University of London, London, UK.
Lancet Oncol ; 21(1): 105-120, 2020 01.
Article en En | MEDLINE | ID: mdl-31753727
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Carcinoma de Células Transicionales / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias Urológicas / Terapia Recuperativa Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Carcinoma de Células Transicionales / Protocolos de Quimioterapia Combinada Antineoplásica / Neoplasias Urológicas / Terapia Recuperativa Tipo de estudio: Clinical_trials / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male / Middle aged Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2020 Tipo del documento: Article